Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

INTRODUCTION: Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are much greater than those for treating drug-susceptible TB, both for health service and patient-incurred costs. Urgent...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeney, Sedona, Gomez, Gabriela, Kitson, Nichola, Sinha, Animesh, Yatskevich, Natalia, Staples, Suzanne, Moodliar, Ronelle, Motlhako, Sharon, Maloma, Matshepo, Rassool, Mohammed, Ngubane, Nosipho, Ndlovu, Ella, Nyang'wa, Bern-Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549492/
https://www.ncbi.nlm.nih.gov/pubmed/33039989
http://dx.doi.org/10.1136/bmjopen-2019-036599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549492/
https://www.ncbi.nlm.nih.gov/pubmed/33039989
http://dx.doi.org/10.1136/bmjopen-2019-036599

Ejemplares similares